Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drug Metabolism: Phase I Reactions01:17

Drug Metabolism: Phase I Reactions

2.9K
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
2.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

401
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
401
First Pass Effect01:12

First Pass Effect

4.9K
Presystemic elimination, or the first-pass effect, is the metabolism of drugs that reduces their effective concentration at the site of action. Apart from the first-pass effect, the systemic bioavailability of the drug is also reduced by other factors, including incomplete absorption or chemical degradation of drugs.
Depending on the route of administration, drugs can be metabolized in the liver, intestine, lungs, and vasculature. Orally administered drugs are first absorbed through the...
4.9K
Factors Influencing Bioavailability: First-Pass Elimination01:23

Factors Influencing Bioavailability: First-Pass Elimination

6.0K
When a drug is taken orally, it undergoes a journey starting from the gastrointestinal (GI) tract, passing through the portal vein, reaching the liver, and finally entering the systemic circulation. This process involves the absorption of the drug across the GI tract. The liver is the primary site for metabolizing the drug, with some metabolism also occurring in the gut wall. This journey significantly reduces the quantity of the drug that reaches the systemic circulation, a phenomenon known as...
6.0K
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

299
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
299
Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

3.5K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.5K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Tividenofusp Alfa: First Approval.

Molecular diagnosis & therapy·2026
Same author

Milsaperidone: First Approval.

Clinical drug investigation·2026
Same author

Narsoplimab: First Approval.

Drugs·2026
Same author

Aficamten: First Approval.

Drugs·2026
Same author

Elamipretide: First Approval.

Drugs·2025
Same author

Aztreonam-Avibactam: A Review in the Treatment of Serious Bacterial Infections Caused by Aerobic Gram-Negative Organisms.

Drugs·2025
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
查看所有相关文章

相关实验视频

Updated: May 22, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

940

斯塔波基巴特:第一次获得批准

Matt Shirley1

  • 1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|March 17, 2025
PubMed
概括
此摘要是机器生成的。

新型生物疗法Stapokibart在中国首次获得批准,用于治疗中度至重度的亚托皮炎. 这种介素-4受体α (IL-4Rα) 抑制剂向2型炎症通路,提供了一种新的治疗选择.

更多相关视频

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

31.7K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.2K

相关实验视频

Last Updated: May 22, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

940
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

31.7K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.2K

科学领域:

  • 免疫学 免疫学 免疫学
  • 药理学 药理学是指药理学的学科.
  • 皮肤病学 皮肤病学

背景情况:

  • 亚托皮炎是一种慢性炎症性皮肤疾病.
  • 2型细胞因子,包括IL-4和IL-13,在亚托皮性皮炎的发病过程中起着关键作用.
  • 准IL-4受体α (IL-4Rα) 子单元提供了一个潜在的治疗策略.

研究的目的:

  • 为了总结Stapokibart的发展里程碑.
  • 为了突出第一个监管批准的stapokibart对亚托皮性皮肤炎.
  • 提供Stapokibart的作用机制和治疗潜力的概述.

主要方法:

  • 开发了stapokibart,一种人性化的IgG4单克隆抗体.
  • 准介素-4受体α (IL-4Rα) 子单元.
  • 阻断IL-4和IL-13的信号通路.

主要成果:

  • 斯泰波基巴特于2024年9月在中国首次获得批准,用于中度至重度的亚托邦性皮肤炎.
  • 随后在中国批准的药物包括带有鼻息肉的慢性鼻炎和季节性过敏性鼻炎.
  • 斯塔波基巴特正在临床评估喘,慢性肺炎和结节炎.

结论:

  • 斯塔波基巴特在治疗2型炎症性疾病方面取得了重大进展.
  • 批准标志着KeyMed生物科学和阿托皮性皮肤炎患者的关键里程碑.
  • 进一步的临床评估正在进行中,以扩大stapokibart的治疗应用.